- Home
- PVL vs IMA Comparison
PVL vs IMA Comparison
Compare PVL & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$4.55
Company Overview
Basic Information| Metric | PVL | IMA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7M | 65.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVL | IMA |
|---|---|---|
| Price | $1.86 | $4.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 107.4K | 38.5K |
| Earning Date | 03-20-2026 | 05-15-2026 |
| Dividend Yield | ★ 7.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $3.94 |
| 52 Week High | $2.04 | $17.50 |
Technical Indicators
Market Signals| Indicator | PVL | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 24.72 |
| Support Level | $1.75 | $3.94 |
| Resistance Level | $1.89 | $7.28 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 25.00 | 28.46 |
Price Performance
Historical Comparison PVL
IMA
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.